Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The ClinicalTrials.gov page’s footer revision changes from v3.8.0 to v3.8.1; the study content remains unchanged.
    Difference
    0.1%
    Check dated 2026-11-22T14:51:31.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The clinical trial record for androgen deprivation therapy combined with pembrolizumab is displayed, with details about the study design, participant eligibility, participating locations, and measured outcomes.
    Difference
    51%
    Check dated 2026-11-08T14:36:39.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 error.
    Difference
    0.3%
    Check dated 2026-11-01T15:49:24.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A dismissible NIH banner announces website updates and a transition from “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-25T15:37:30.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page displays an updated site revision identifier, from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T22:20:57.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T21:57:33.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.